Secondary Data Analysis Of Newly Diagnosed Advanced Ovarian Cancer In South Korea

Epithelial ovarian cancer patients often present at an advanced stage of disease with a poor prognosis and high mortality. Considering the high disease burden and the evolving ovarian cancer treatment landscape, it is important to assess longitudinal data from available registry. This helps in identifying patient management patterns and survival outcomes arising from current standard of care. This study aims to analyze existing secondary database from Samsung Medical Center, Seoul, South Korea to review the current standard of care in real world setting. This is a retrospective observation study with access to retrospective database of patients diagnosed with advanced-stage epithelial ovarian cancer in 5-years, between Jan 2014–Dec 2018. In the database, the number of patients met the criteria was 513 and the median age was 56. The percentage of high-grade serous adenocarcinoma was 84.6%. General treatment characteristics including use of neoadjuvant and/or adjuvant treatment, outcomes of cytoreductive surgery as well as use of bevacizumab is summarized with descriptive statistics. The proportion of patients underwent platinum-based chemotherapy was 98.6%. Among these patients, 14.6% took additional maintenance treatment with bevacizumab or other agents. Duration of treatment other time to event measures (e.g. overall survival, chemotherapy-free interval) will be evaluated descriptively using Kaplan–Meier methodology, together with two-sided 95% confidence intervals (95% CIs) for the median survival estimates. Advanced stage ovarian cancer presents poor prognosis and high morbidity even in South Korea with well-developed healthcare systems and requires novel approaches to improve patient outcomes.